ES2168295T3 - Factor estimulante oseo. - Google Patents
Factor estimulante oseo.Info
- Publication number
- ES2168295T3 ES2168295T3 ES94908917T ES94908917T ES2168295T3 ES 2168295 T3 ES2168295 T3 ES 2168295T3 ES 94908917 T ES94908917 T ES 94908917T ES 94908917 T ES94908917 T ES 94908917T ES 2168295 T3 ES2168295 T3 ES 2168295T3
- Authority
- ES
- Spain
- Prior art keywords
- gly
- polypeptide
- lys
- ala
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
UNA SUSTANCIA DE POLIPEPTIDO AISLADA DE SUERO DE RATA QUE, AL ADMINISTRAR A RATAS INCAPACES DE PRODUCIR PTH (RATAS PARATIROIDEMIZADAS), PRODUCE UN AUMENTO EN LA PROPORCION DE AÑADIDO MINERAL DE HUESO. LAS SUSTANCIA HA SIDO AISLADA EN DOS FORMAS, UNA PRIMER POLIPEPTIDO MAYOR QUE TIENE UN PESO MOLECULAR DE APROXIMADAMENTE EL DOBLE DEL DE UN SEGUNDO POLIPEPTIODO MENOR. LOS 11 PRIMEROS AMINOACIDOS DE LA SECUENCIA DEL POLIPEPTIDO MENOR HAN SIDO DETERMINADOS SON GLY PRO GLY GLY ALA GLY GLU TH LYS PRO ILE. LOS 7 PRIMEROS AMINOACIDOS DEL POLIPEPTIDO MAYOR HAN SIDO DETERMINADOS Y SON GLY PRO GLY CLY ALA GLY GLU. EL POLIPEPTIDO MAYOR PUEDE SER EL DIMERO DEL POLPEPTIDO MENOR. UNA ONDA DE ACIDO NUCLEICO, BASADA EN LA SECUENCIA DE AMINOACIDOS DEL PEPTIDO DE RATA FUE USADA PARA FILTRAR UNA LIBRERIA FETAL DE ADNC DE HIGADO HUMANO. UN POLIPEPTIDO FUE ASI QUIMICAMENTE SINTETIZADO DE ACUERDO CON LA SECUENCIA GLY ILE GLY GLY ARG THR ASN GLU HIS THR ALA ASP CYS LYS ILE LYS PRO ASN THR LEU HIS LYS ALA ALA GLU THR LEU MET VAL LEU ASP GLN ASN GLN PRO. LA PROPORCION DE AÑADIDO DE HUESO EN LAS RATAS AUMENTA EN UNA DOSIS QUE DEPENDE DEL MODO DE ADMINISTRACION DE ESTE COMPUESTO QUIMICAMENTE SINTETIZADO.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3138693A | 1993-03-12 | 1993-03-12 | |
| US12021793A | 1993-09-13 | 1993-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2168295T3 true ES2168295T3 (es) | 2002-06-16 |
Family
ID=26707172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94908917T Expired - Lifetime ES2168295T3 (es) | 1993-03-12 | 1994-03-14 | Factor estimulante oseo. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0688360B1 (es) |
| JP (1) | JP3733381B2 (es) |
| KR (1) | KR960701201A (es) |
| CN (1) | CN1119457A (es) |
| AT (1) | ATE208818T1 (es) |
| AU (1) | AU678441B2 (es) |
| BR (1) | BR9406447A (es) |
| CA (1) | CA2157901A1 (es) |
| CZ (1) | CZ234295A3 (es) |
| DE (1) | DE69429082T2 (es) |
| ES (1) | ES2168295T3 (es) |
| FI (1) | FI954252A0 (es) |
| HU (1) | HUT73297A (es) |
| IL (1) | IL108947A0 (es) |
| NO (1) | NO953286L (es) |
| NZ (1) | NZ262352A (es) |
| PL (1) | PL182236B1 (es) |
| TW (1) | TW385314B (es) |
| WO (1) | WO1994020615A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786327A (en) | 1993-03-12 | 1998-07-28 | Gensci Regeneration Sciences Inc. | Bone stimulating factor, methods of isolating same, and methods of increasing bone growth comprising administering same |
| US5880094A (en) * | 1995-06-07 | 1999-03-09 | Osteopharm Limited | Polypeptides that stimulate bone growth |
| US6117839A (en) * | 1995-06-07 | 2000-09-12 | Gensci Regeneration Sciences, Inc. | Bone stimulating factor |
| US6352973B1 (en) | 1995-06-07 | 2002-03-05 | Osteopharm Inc. | Bone stimulating factor |
| US6693081B2 (en) | 1995-09-26 | 2004-02-17 | Osteopharm Inc. | Bone stimulating factor |
| ATE323152T1 (de) | 1997-09-19 | 2006-04-15 | Metabolix Inc | Biologische systeme zur herstellung von polyhydroxyalkanoate polymeren die 4-hydroxysäure enthalten |
| DE19906096A1 (de) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein mit einem Heparin-bindenden Epitop |
| AU5379200A (en) * | 1999-06-02 | 2000-12-28 | Osteopharm Inc. | Bone stimulating factor |
| WO2001016377A2 (en) | 1999-08-30 | 2001-03-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for osteoporosis |
| US6815421B1 (en) | 2001-03-22 | 2004-11-09 | Osteopharm Inc. | Polypeptides for use in ameliorating effects of aging in mammals |
| CA2534365A1 (en) | 2003-08-08 | 2005-02-17 | Interleukin Genetics, Inc. | Diagnostic and therapeutics for osteoporosis |
| US8367602B2 (en) * | 2006-12-21 | 2013-02-05 | Corticalis As | Consensus peptides and a method for inducing biomineralization |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0128041A3 (en) * | 1983-06-06 | 1986-12-03 | David Jeston Baylink | Polypeptides exhibiting skeletal growth factor activity |
| CA2020729A1 (en) * | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
-
1994
- 1994-03-11 IL IL10894794A patent/IL108947A0/xx unknown
- 1994-03-14 BR BR9406447A patent/BR9406447A/pt not_active Application Discontinuation
- 1994-03-14 AU AU61797/94A patent/AU678441B2/en not_active Ceased
- 1994-03-14 HU HU9502659A patent/HUT73297A/hu unknown
- 1994-03-14 ES ES94908917T patent/ES2168295T3/es not_active Expired - Lifetime
- 1994-03-14 DE DE69429082T patent/DE69429082T2/de not_active Expired - Fee Related
- 1994-03-14 JP JP51844794A patent/JP3733381B2/ja not_active Expired - Fee Related
- 1994-03-14 CN CN94191456A patent/CN1119457A/zh active Pending
- 1994-03-14 KR KR1019950703855A patent/KR960701201A/ko not_active Application Discontinuation
- 1994-03-14 EP EP94908917A patent/EP0688360B1/en not_active Expired - Lifetime
- 1994-03-14 CA CA002157901A patent/CA2157901A1/en not_active Abandoned
- 1994-03-14 PL PL94310617A patent/PL182236B1/pl unknown
- 1994-03-14 CZ CZ952342A patent/CZ234295A3/cs unknown
- 1994-03-14 WO PCT/CA1994/000144 patent/WO1994020615A1/en not_active Application Discontinuation
- 1994-03-14 AT AT94908917T patent/ATE208818T1/de not_active IP Right Cessation
- 1994-03-14 NZ NZ262352A patent/NZ262352A/en unknown
- 1994-03-21 TW TW083102552A patent/TW385314B/zh not_active IP Right Cessation
-
1995
- 1995-08-22 NO NO953286A patent/NO953286L/no not_active Application Discontinuation
- 1995-09-11 FI FI954252A patent/FI954252A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2157901A1 (en) | 1994-09-15 |
| DE69429082D1 (de) | 2001-12-20 |
| WO1994020615A1 (en) | 1994-09-15 |
| BR9406447A (pt) | 1996-02-13 |
| IL108947A0 (en) | 1994-06-24 |
| CZ234295A3 (en) | 1996-04-17 |
| KR960701201A (ko) | 1996-02-24 |
| JP3733381B2 (ja) | 2006-01-11 |
| NO953286D0 (no) | 1995-08-22 |
| DE69429082T2 (de) | 2002-07-25 |
| NO953286L (no) | 1995-10-25 |
| AU6179794A (en) | 1994-09-26 |
| JPH08508158A (ja) | 1996-09-03 |
| HU9502659D0 (en) | 1995-11-28 |
| ATE208818T1 (de) | 2001-11-15 |
| EP0688360B1 (en) | 2001-11-14 |
| FI954252A (fi) | 1995-09-11 |
| FI954252A0 (fi) | 1995-09-11 |
| CN1119457A (zh) | 1996-03-27 |
| TW385314B (en) | 2000-03-21 |
| AU678441B2 (en) | 1997-05-29 |
| EP0688360A1 (en) | 1995-12-27 |
| NZ262352A (en) | 1997-10-24 |
| HUT73297A (en) | 1996-07-29 |
| PL310617A1 (en) | 1995-12-27 |
| PL182236B1 (pl) | 2001-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gregory et al. | The primary structure of human urogastrone | |
| Weber et al. | Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina | |
| EP1053255A4 (en) | THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS, AND USES THEREOF | |
| ES2168295T3 (es) | Factor estimulante oseo. | |
| EP1175909A3 (en) | Therapeutic methods and compositions based on serrate proteins and nucleic acids | |
| IE850436L (en) | Peptides | |
| PT861261E (pt) | Sequências nucleotídicas e proteicas de genes delta de vertebrado e métodos nelas baseados | |
| DE3486154D1 (de) | Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung. | |
| ATE386118T1 (de) | Cnp-gen und vorläuferprotein aus schwein | |
| RU93045577A (ru) | Слитные полипептиды | |
| AU5963290A (en) | Inhibition of the n-end rule pathway in living cells | |
| Gelher et al. | The sequence of an atriopeptigen: a precursor of the bioactive atrial peptides | |
| JPS646219A (en) | Peptide having promoting action on activation of protein c by thrombin | |
| US5814610A (en) | Osteogenic growth oligopeptides and pharmaceutical compositions containing them | |
| STEWART et al. | Synthetic parathyroid hormone-like protein-(1–74): Biochemical and physiological characterization | |
| DE60109412T2 (de) | Therapeutische peptide | |
| CA2163212A1 (en) | Therapeutic compounds | |
| FERRARA et al. | β‐Endorphin: Interaction of synthetic analogs having different chain lengths with morphine and enkephalin receptors in rat brain membranes | |
| FR2691153B1 (fr) | Dodecapeptides monomere et dimere, utilisation en tant qu'agents anti-megacaryocytaires. | |
| Monet et al. | In vitro relative biological activities of (1--34) N-terminal synthetic fragments of human parathyroid hormone in the human renal cortical adenylate cyclase assay | |
| JP2796835B2 (ja) | ヒトカルパスタチン様ポリペプチド | |
| Ganeshan et al. | Recognition of neuropeptides FMRFamide and LPLRFamide by chicken cerebellum avian pancreatic polypeptide binding sites | |
| JPH07278191A (ja) | 新規ペプチドもしくは蛋白質及びそれを探索する方法 | |
| TH35998A (th) | Lh-rh เป็ปไทด์ อะนาล็อก ประโยชน์ของสิ่งเหล่านั้นและองค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วยสิ่งเหล่านั้น | |
| RU93058426A (ru) | Антогонист галанина, способ его получения, пептид, фармацевтический состав и способ лечения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 688360 Country of ref document: ES |